Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.52 |
| ▸ | NPC1 | O15118 | 9/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.51 |
| ▸ | RELA | Q04206 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651937 | 0.83 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2MAPTSTAT3 | |
| SCHEMBL2216313 | 0.83 | FYN (0.56) | RAB9ANPC1SMN1; SMN2MAPTSTAT3 | |
| SCHEMBL4796772 | 0.83 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2MAPTSTAT3 | |
| SCHEMBL14268230 | 0.81 | CYP11B1 (0.52) | RAB9ANPC1SMN1; SMN2MAPTSTAT3 | |
| SCHEMBL15783685 | 0.81 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2MAPTSTAT3 | |
| SCHEMBL8511970 | 0.80 | CASP3 (0.74) | RAB9ANPC1SMN1; SMN2MAPTSTAT3 | |
| SCHEMBL27705919 | 0.80 | CYP11B1 (0.51) | RAB9ANPC1SMN1; SMN2MAPTSTAT3 | |
| SCHEMBL2651325 | 0.79 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2MAPTSTAT3 | |
| SCHEMBL8452469 | 0.79 | SMN1; SMN2 (0.62) | RAB9ANPC1SMN1; SMN2MAPTSTAT3 | |
| SCHEMBL2653790 | 0.78 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2MAPTSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518976-B2 | e.g. 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)-1H-pyridin-2-one; endothelial nitric oxide NO synthase inhibitor; antiinflammatory, hypotensive agent; atherosclerosis, thrombosis, coronary artery disease, and cardiac insufficiency | SANOFI (FR) | 2013-08-27 | — | — | US | disclosed |
| EP-1899321-B1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-28 | — | — | EP | disclosed |
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-07-17 | — | — | US | disclosed |
| EP-1899321-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | disclosed |
| EP-1741709-A1 | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2007000246-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | TBXAS1, PTGIS, NOS2 | RAB9A 3899/4885NPC1 2812/4885SMN1; SMN2 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.